-
External JAK inhibitor to treat eczema Incyte using priority review vouchers submitted...
Time of Update: 2021-03-07
Retrieved February 19, 2021, from Ruxolitinib Cream: Phase 3 Data in Atopic Dermatitis.
-
Coating service provider Science and Technology has entered the ranks of the new three-board review
Time of Update: 2021-03-07
China Coatings Network : Coating service provider Guangdong Science and Technology Co., Ltd. (hereinafter referred to as "Kofu Technology") officially entered the ranks of the new three-board review. reporter learned that in 2011
-
Environmental reviews of coal chemical projects are tightening
Time of Update: 2021-03-07
chemical industry. Chen Bin, a professor at Beijing Normal University's School of The Environment, read the news in an interview with the China Chemical News. He believes that the government has begun to learn lessons, China's environmental review of coal
-
Review of the EU 2020 PRIME Priority Medicines Program
Time of Update: 2021-03-07
to be reviewed under the EMA's accelerated evaluation mechanism. this means that fast tracks are not established and it is not uncommon for products through PRIME to be reviewed within the standard time range. 84 determinations have been
-
FDA responds to criticism of Alzheimer's drug review process by refusing to pre-declaration and claim...
Time of Update: 2021-03-07
, Public Citizen, a consumer advocacy group, issued a scathing letter of criticism about the FDA's review process for Biogen's controversial Aducanumab listing, saying that Billy Dunn, director of the Office of Neuroscience, and other reviewers had
-
receives FDA Priority Review: Significantly Extending Disease-Free Survival!
Time of Update: 2021-03-06
) and a centralized review process has been initiated. application is based on the results of Phase 3 CheckMate-577 trials. data show that opdivo-assisted therapy doubled the patient's disease-free survival (DFS) (median DFS: 22.4 months vs
-
Serum-free cryopreservation of five mammalian cell lines in either a pelleted or suspended state
Time of Update: 2021-03-06
Second, we compared cryostorage of those cells in suspended versus a pellet form using both aforementioned cryopreservatives.
-
2020 Domestic CRO Industry Review
Time of Update: 2021-03-06
key materials to fight the outbreak include testing reagents, vaccines, drugs, and some medical devices, and research and development and production units are working overtime, with CRO companies that can provide supporting services.
-
Scientists find wheat "cancer" star Yuan Long equal review
Time of Update: 2021-03-06
of which are quite resistant. Niu Jishan, an associate researcher at the National Wheat Engineering Center of Henan Agricultural University, and others mentioned in the study review that the genetic background had an effect on the resistance of Fhb1
-
3 new drugs to be included in the priority review!
Time of Update: 2021-03-06
Supi Medicine's new rare disease drug Nitesinon capsules, the proposed development of adaptive disorders are: combined with tyrosine and phenylalanine dietary restrictions, for the treatment of adult and pediatric patients (at any age) hereditary HT-1.
-
AstraZeneta's Tagrisso gets FDA priority review
Time of Update: 2021-03-06
AstraZeneca's EGFR tyrosine kinase inhibitor Tagrisso has been given priority review by the U.S. Food and Drug Administration (FDA) to treat lung cancer with early EGFR mutations. In particular, AstraZenecom
-
Detection of Beta-Blockers in Urine and Serum by Solid-Phase Extraction-Supercritical Fluid Extraction and Gas Chromatography-Mass Spectrometry
Time of Update: 2021-03-05
Beta-blockers have some clinical use in the treatment of angina pectoris, hypertension, and tachycardia. In addition, they have been used to control migraine, chronic alcoholism, schizophrenia, essential tremor, and cardiac effects
-
GlaxoSmithKline's dual-drug HIV therapy is to be included in the priority review
Time of Update: 2021-03-05
China's State Drug Administration Drug Review Center (CDE) recently announced that the two-drug HIV therapy submitted by GlaxoSmithKline (GSK) - Dotiravirpivirin tablets of the new drug market application to be included in the priority review
-
Sanofi Pompe bay disease therapy is eligible for FDA priority review
Time of Update: 2021-03-05
A key double-blind drug-controlled Phase 3 clinical trial assessed the safety and efficacy of avalglucosidase alfa compared to α-glucosidease (standard treatment) in patients with late-haired Pompeidase.
-
Several new drugs are to be included in the priority review!
Time of Update: 2021-03-05
source: CDE 1, AbbVie's JAK inhibitor upadacitinib two listing applications to be included in the priority review, the development of adaptive disorders for systemic treatment for adults and adolescents aged 12 years and over moderate severe specialty dermatitis patients.
-
Phospholipases in Food Industry: A Review
Time of Update: 2021-03-05
This is because the use of phospholipases in the production of specific foods leads to attractive advantages, such as yield improvement, energy saving, higher efficiency, improved properties, or better quality of the final product.
-
New medicine for rare lung disease! Roche Esbriet (pyridone) is reviewed by the FDA as a priority
Time of Update: 2021-03-04
phase II clinical trial data show that Esbriet slowed the progression of the disease in UIDD patients at 24 weeks of treatment compared to a placebo.
-
(voxelotor), is under EU review and is on the market in the US!
Time of Update: 2021-03-03
maa sought full approval from the EMA for Oxbryta to treat hemolytic anemia in patients aged 12 years and older with sickle cell disease (SCD).
-
Progress was made in the evaluation of silver ring snake toxin and clinical anti-silver ring snake serum
Time of Update: 2021-03-03
The Biotoxin and Human Diseases Unit of the Kunming Institute of Zoology of the Chinese Academy of Sciences studied silver ring snakes and obtained high-purity a-bungarotoxin, b-bungarotoxin and g-bungarotoxin by traditional separation and purification methods.
-
New Alzheimer's (AD) drug! The review period of β protein antibody aducanumab was extended by 3 months by the FDA!
Time of Update: 2021-03-03
